EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

A meta-analysis on the efficacy and safety of obinuzumab for membranous nephropathy

Li-Xia Yu, Chuan-Li Qian, Jing-Rong Qian, Qi-Zhang, Xu-Li Yang, Qi-Feng Liu iD

Sage Open Chronic Disease · 2026-02 · 17

DOI: 10.1177/27558428261421704 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Sage Open Chronic Disease, online erschienen am 27.03.2026. Verfasst von Li-Xia Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Jiangsu, China. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Education Collaborative Innovation Fund, Jiangsu University, the “National Tutorial System” Training Program for Key Young Health Professionals in Suzhou, Medical Research Project, Jiangsu Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The management of idiopathic membranous nephropathy (IMN) continues to be a significant challenge to date. A limited number of observational studies have compared Obinutuzumab’s (OBZ) therapeutic potential, with OBZ appearing to be more effective than rituximab (RTX) in achieving clinical remission.

Objective

This study was designed to evaluate the effectiveness and safety profile of OBZ for IMN treatment.

Design

Clinical studies regarding the application of OBZ for IMN were included, and the effector sizes were pooled by meta-analysis. Sensitivity analysis and subgroup analysis were adopted to evaluate the robustness and reliability of the findings. Data sources and methods: Several electronic databases were systematically searched for relevant studies. Effectors, including the rates of total remission (TR) and complete remission (CR), reported in these studies were extracted and pooled as non-comparative binary variables. The rates of immunologic remission, B-cell depletion, and adverse events (AEs) were recorded.

Results

Among the studies retrieved in the initial search, 9 eligible studies with 344 participants were included in this meta-analysis. OBZ therapy increased the TR rates at 6 months (0.78 (0.71, 0.85)) and 12 months (0.88 (0.82, 0.93)) and improved the CR rates at 6 months (0.13 (0.03, 0.23)) and 12 months (0.27 (0.16, 0.39)) compared to RTX. No evident heterogeneity or publication bias was observed. The results persisted in the subgroup analysis in terms of OBZ, as the initial treatment for membranous nephropathy (MN), for refractory MN, or for RTX-refractory MN. Interestingly, OBZ treatment was linked to a greater probability of achieving TR than RTX treatment (At 6 months, odds ratio was 4.07 (1.94, 8.53)) and (At 12 months, odds ratio was 10.79 (3.38, 34.39)). OBZ therapy consistently led to a relatively high rate of immunological remission and effective B-cell clearance and did not increase the incidence of AEs or severe AEs.

Conclusion

OBZ therapy is associated with improved clinical remission and might be an attractive option for patients with IMN, especially those with refractory or RTX-refractory IMN. High-quality clinical studies are, however, warranted to validate these results further.

Trial registration

This study was registered as a meta-analysis in PROSPERO (Number: CRD42025635162).

Schlagwörter

Stichwörter der Autor:innen

CD20 antibodyefficacymembranous nephropathyobinutuzumabphospholipase A2 receptor

Autor:innen und Institutionen

  • Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Jiangsu, China.
  • Gusu School, The First People's Hospital of Kunshan, Nanjing Medical University, Kunshan, Jiangsu, China.

ORCID-Profile: Qi-Feng Liu

Förderung

  • Medical Education Collaborative Innovation Fund, Jiangsu University
  • the “National Tutorial System” Training Program for Key Young Health Professionals in Suzhou
  • Medical Research Project, Jiangsu Provincial Health Commission

Zitieren

APA

Yu, L. X., Qian, C. L., Qian, J. R., Qi-Zhang, Yang, X. L., & Liu, Q. F. (2026). A meta-analysis on the efficacy and safety of obinuzumab for membranous nephropathy. Sage Open Chronic Disease, 17. https://doi.org/10.1177/27558428261421704

Vancouver

Yu LX, Qian CL, Qian JR, Qi-Zhang, Yang XL, Liu QF. A meta-analysis on the efficacy and safety of obinuzumab for membranous nephropathy. Sage Open Chronic Disease. 2026;17. doi:10.1177/27558428261421704

BibTeX
@article{Yu2026,
  author = {Yu, Li-Xia and Qian, Chuan-Li and Qian, Jing-Rong and Qi-Zhang and Yang, Xu-Li and Liu, Qi-Feng},
  title = {A meta-analysis on the efficacy and safety of obinuzumab for membranous nephropathy},
  journal = {Sage Open Chronic Disease},
  year = {2026},
  volume = {17},
  doi = {10.1177/27558428261421704}
}
Kostenlos starten →